Matches in Nanopublications for { ?s ?p "[Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- assertion description "[Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP381478.RAVnh-BTxqwqXtuJzZiOzDNFJFPL6d4ppfGbT3X-Al8y8130_assertion description "[Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP381478.RAVnh-BTxqwqXtuJzZiOzDNFJFPL6d4ppfGbT3X-Al8y8130_provenance.
- NP382032.RAe2Rh2Y8zgWxCU8cCuOIk_Mb3dUT7kmixm1XUt1gDb-o130_assertion description "[Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP382032.RAe2Rh2Y8zgWxCU8cCuOIk_Mb3dUT7kmixm1XUt1gDb-o130_provenance.
- NP1182855.RAN-qY6lBZ1EyPq6FfqvkEtX49Bh1ejkqinOz451feFLw130_assertion description "[Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1182855.RAN-qY6lBZ1EyPq6FfqvkEtX49Bh1ejkqinOz451feFLw130_provenance.
- NP1182859.RA0ACTviS39bwYAFluIbMmx6ymNQVDbUiWHOAW7zobInA130_assertion description "[Our purpose is to evaluate the predictive value of the genetic polymorphisms of Excision repair cross-complementing group 1 (ERCC1) and xeroderma pigmentosum group D/excision repair cross-complementing group 2 (XPD/ERCC2) in patients with advanced colorectal cancer receiving oxaliplatin-based chemotherapy, and we performed a meta-analysis in order to obtain a more precise estimation for a more optimizing individual chemotherapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1182859.RA0ACTviS39bwYAFluIbMmx6ymNQVDbUiWHOAW7zobInA130_provenance.